Guardant Health (GH) reported $982M in revenue for fiscal 2025, +32.9% year on year. That ranks #1780 by revenue among 2853 SEC filers and #162 in Healthcare. It posted a net loss of −$416M for the same year. Revenue has grown 50.2% a year on average since 2016 ($25.2M then). The fiscal 2025 balance sheet shows $2.0B in total assets, $378M in cash and $1.5B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $982M | +32.9% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$437M | +$6.3M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$416M | +$20.1M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$185M | +$55.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $48.3M | +37.7% | FY20252025-12-31 |
| Total assetsAssets | $2.0B | +35.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$99.3M | +$40.3M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $378M | −28.0% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $1.5B | +31.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $302M | −$112M | Open → |
| Q2 20262026-06-30 | $335M | −$120M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Guardant Health, Inc.
- Ticker
- GH
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001576280
Filings
- 10-QJul 30, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Acadia PharmaceuticalsACAD | $1.1B | $391M |
| Legend BiotechLEGN | $1.0B | −$297M |
| Tandem Diabetes CareTNDM | $1.0B | −$205M |
| Guardant HealthGH | $982M | −$416M |
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
| Pennant GroupPNTG | $948M | $29.6M |
| Ionis PharmaceuticalsIONS | $944M | −$381M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Guardant Health — Key figures |url=https://companiesranked.com/en/company/guardant-health |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Guardant Health — Key figures. CompaniesRanked. https://companiesranked.com/en/company/guardant-healthBibTeX
@misc{companiesranked-en-company-guardant-health-2026,
author = {{CompaniesRanked}},
title = {{Guardant Health — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/guardant-health}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001576280-26-000013 · February 19, 2026
{{cite web |title=Guardant Health — Key figures — 10-K (0001576280-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1576280/000157628026000013/gh-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.